$80.24
$153.25
Description Gonadorelin Acetate CAS Number 34973-08-5 Molar Mass 1242.3 g·mol−1 Chemical Formula C57H79N17O15 IUPAC Name L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-glycyl-L-leucyl-L-arginyl-L-prolyl-glycinamide acetic acid Brief Introduction Gonadorelin Acetate is a peptide designed for research purposes, specifically targeting the gonadotropin-releasing hormone (GnRH) receptors. This synthetic analog of GnRH plays a crucial role in reproductive health and hormonal regulation. It is important to note that this product is intended for research applications only and not for human consumption. Key Characteristics Gonadorelin Acetate is characterized by its ability to stimulate the secretion of gonadotropins, including luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These characteristics make it a valuable tool for investigating various aspects of reproductive physiology. Research Applications Researchers utilize Gonadorelin Acetate in a variety of studies focusing on reproductive health, endocrinology, and related fields. Its unique properties make it an essential component in understanding the intricate mechanisms of hormonal regulation. Research Benefits Breast Cancer Prevention Studies have explored the potential of Gonadorelin Acetate in breast cancer prevention by investigating its impact on hormonal pathways. Research has suggested its involvement in modulating estrogen levels, a key factor in breast cancer development. Male Infertility Studies Gonadorelin Acetate has been a subject of research in male infertility studies, aiming to comprehend its role in regulating reproductive hormones and addressing issues related to spermatogenesis. Bone Mineral Density Research Research applications extend to bone health studies, where Gonadorelin Acetate is employed to examine its influence on bone mineral density and potential implications for conditions like osteoporosis. Disclaimer This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE. Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA). Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made. Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at
[email protected]. IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization. Summary In summary, Gonadorelin Acetate stands as a valuable research tool, contributing to studies across diverse domains such as breast cancer prevention, male infertility, and bone mineral density research. Researchers utilize this synthetic peptide to deepen our understanding of reproductive physiology and associated health aspects. It is imperative to emphasize that Gonadorelin Acetate is strictly intended for research purposes and should not be used for human consumption. References Huerta-Reyes M, Maya-Núñez G, Pérez-Solis MA, López-Muñoz E, Guillén N, Olivo-Marin JC, Aguilar-Rojas A. Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs. Front Oncol. 2019 Oct 1;9:943. doi: 10.3389/fonc.2019.00943. PMID: 31632902; PMCID: PMC6779786. [Read More]. Rajkanna J, Tariq S, Oyibo SO. Successful fertility treatment with gonadotrophin therapy for male hypogonadotrophic hypogonadism. Endocrinol Diabetes Metab Case Rep. 2016;2016:150124. doi: 10.1530/EDM-15-0124. Epub 2016 Jan 7. PMID: 26807263; PMCID: PMC4722247. [Read More]. Chen-Xi Li, Song-Tao Tang, Qiu Zhang, “Changes in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic Hypogonadism”, International Journal of Endocrinology, vol. 2015, Article ID 324524, 5 pages, 2015. https://doi.org/10.1155/2015/324524. [Read More].
